◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › AGEN

Agenus Inc. (AGEN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-26

Agenus Inc. (AGEN) operates in the Biotechnology industry and is headquartered in Lexington, United States with about 81 employees. Its market capitalization is roughly $249 million. In the fiscal year ended 2025-12-31, AGEN reported $114M in revenue and $0M in net income.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.

Interactive charts & full statements → Open the AGEN valuation workbench →

AGEN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$114M$104M$156M$98M
Gross Profit$34M($53M)($81M)($99M)
Operating Income (EBIT)($21M)($124M)($160M)($180M)
Net Income$0M($227M)($246M)($220M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGEN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$34M$34M$30M$26M$24M
Gross Profit$22M$27M$6M($1M)$2M
Operating Income (EBIT)$15M$14M($5M)($17M)($13M)
Net Income$39M($11M)$64M($28M)($25M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGEN Free Cash Flow History

AGEN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$227M$226M$314M$414M
Total Liabilities$505M$533M$462M$468M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGEN viewer.

Other Companies in Biotechnology

← AGCOAll stocksAGI →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.